Novel animal model of calvarial defect: Part III. reconstruction of an irradiated wound with rhBMP-2

Plastic and Reconstructive Surgery

Volumn 130, Issue 5, 2012, Pages

  Kinsella, Christopher R ^a   MacIsaac, Zoe M ^a   Cray, James J ^a   Smith, Darren M ^a   Rottgers, S Alex ^a   Mooney, Mark P ^a   Cooper, Gregory M ^a   Losee, Joseph E ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; AUTOTRANSPLANTATION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CRYOPRESERVATION; DISEASE MODEL; DRUG EFFECT; INJURY; MALE; PLASTIC SURGERY; RABBIT; RADIATION DOSE; RADIATION EXPOSURE; RADIOGRAPHY; SKULL; TRANSPLANTATION; WOUND HEALING;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CRYOPRESERVATION; DISEASE MODELS, ANIMAL; MALE; RABBITS; RADIATION DOSAGE; RECOMBINANT PROTEINS; RECONSTRUCTIVE SURGICAL PROCEDURES; SKULL; TOMOGRAPHY, X-RAY COMPUTED; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, AUTOLOGOUS; WOUND HEALING;

EID: 84871771691     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318267d412     Document Type: Article

References (23)

1. Food and Drug Administration. Spine indication letter. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf/P000058a.pdf. Accessed November 18, 2011.
2. Food and Drug Administration. Tibia indication letter. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf/p000054a.pdf. Accessed November 18, 2011.
3. Food and Drug Administration. Maxillary sinus and alveolar ridge indication letter. Available at: http://www.accessdata. fda.gov/cdrh-docs/pdf5/ P050053b.pdf. Accessed November 18, 2011.
4. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech. 2002;15:337-349.
5. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84:2123-2134.
6. Wikesjo UM, Qahash M, Polimeni G, et al. Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: Histologic observations. J Clin Periodontol. 2008;35:1001-1010.
7. Doyle JW, Li YQ, Salloum A, FitzGerald TJ, Walton RL. The effects of radiation on neovascularization in a rat model. Plast Reconstr Surg. 1996;98:129-135; discussion 136-139.
8. Larsen PE, Stronczek MJ, Beck FM, Rohrer M. Osteointegration of implants in radiated bone with and without adjunctive hyperbaric oxygen. J Oral Maxillofac Surg. 1993;51: 280-287.
9. Marx RE. Osteoradionecrosis: A new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41:283-288.
10. Decesare GE, Cooper GM, Smith DM, et al. Novel animal model of calvarial defect in an infected unfavorable wound: Reconstruction with rhBMP-2. Plast Reconstr Surg. 2011;127: 588-594.
11. He D, Genecov DG, Herbert M, et al. Effect of recombinant human bone morphogenetic protein-2 on bone regeneration in large defects of the growing canine skull after dura mater replacement with a dura mater substitute. J Neurosurg. 2010;112:319-328.
12. Smith DM, Afifi AM, Cooper GM, Mooney MP, Marra KG, Losee JE. BMP-2-based repair of large-scale calvarial defects in an experimental model: Regenerative surgery in cranioplasty. J Craniofac Surg. 2008;19:1315-1322.
13. Ames CP, Smith JS, Preul MC, et al. Effect of recombinant human bone morphogenetic protein-2 in an experimental model of spinal fusion in a radiated area. Spine (Phila Pa 1976) 2005;30:2585-2592.
14. Kinsella C Jr, Cray JJ, Smith DM, et al. Novel model of calvarial defect: Part II. Reconstruction of an unfavorable scarred wound with rhBMP-2. J Craniofac Surg. 2012; 23:410-414.
15. Takagi K, Urist MR. The reaction of the dura to bone morphogenetic protein (BMP) in repair of skull defects. Ann Surg. 1982;196:100-109.
16. Aitasalo K. Bone tissue response to irradiation and treatment model of mandibular irradiation injury: An experimental and clinical study. Acta Otolaryngol Suppl. 1986;428:1-54.
17. Duncan W, Nias AH, eds. Clinical Radiobiology. Edinburgh, United Kingdom: Churchill Livingston; 1977.
18. Beumer J, Harrison R, Sanders B, Kurrasch M. Osteoradionecrosis: Predisposing factors and outcomes of therapy. Head Neck Surg. 1984;6:819-827.
19. Bras J, de Jonge HK, van Merkesteyn JP. Osteoradionecrosis of the mandible: Pathogenesis. Am J Otolaryngol. 1990;11: 244-250.
20. Nussenbaum B, Rutherford RB, Krebsbach PH. Bone regeneration in cranial defects previously treated with radiation. Laryngoscope 2005;115:1170-1177.
21. Wurzler KK, DeWeese TL, Sebald W, Reddi AH. Radiationinduced impairment of bone healing can be overcome by recombinant human bone morphogenetic protein-2. J Craniofac Surg. 1998;9:131-137.
22. Howard BK, Brown KR, Leach JL, Chang CH, Rosenthal DI. Osteoinduction using bone morphogenic protein in irradiated tissue. Arch Otolaryngol Head Neck Surg. 1998;124:985-988.
23. Jegoux F, Malard O, Goyenvalle E, Aguado E, Daculsi G. Radiation effects on bone healing and reconstruction: Interpretation of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:173-184.